We are extremely proud that Hong Kong has ranked as the world’s #1 IPO venue in seven of the last eleven years. This success in attracting global issuers and investors is testament to the opportunities available in Asia’s most dynamic and vibrant capital markets. In 2019 a total of 183 companies raised HK$314 billion – the highest amount raised in a single year since 2010. And, despite recent global market volatility, our primary market continues to top the world’s IPO fundraising league tables.
In April 2018 we introduced new chapters to our listing rules, for the first time, opening doors to pre-revenue biotech companies and new economy companies. Since then, we have welcomed 109 new economy companies , including 21 biotech companies and 8 secondary listing companies
[1] together, raising a total of HK$457 billion.
Following Alibaba’s successful HK$101 billion listing in 2019, we have continued to attract more new economy companies and welcome some of the world’s biggest IPOs. In 2020, including the secondary listings of NetEase at HK$24.3 billion and JD.com at HK$34.6 billion. We remain focused on enhancing our processes and market infrastructure to make Hong Kong, and HKEX, an ever more attractive listing venue for companies from Hong Kong, Asia and around the world.
To find out more about our Markets, the benefits of "going public", the IPO process and the requirements for listing on our markets, please contact our
Global Issuer Services team.
【1】Including Zai Lab Ltd., which is classified both as biotech company and secondary listing company.
